Tesla's problems, Eli Lilly's weight loss pill, and egg prices surge: Business news roundup

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

“We feel that a product like an oral, orforglipron, could serve a significant amount of patients globally,” Eli Lilly CFO Lucas Montarce said Monday at the Leerink (SIVB) 2025 Global Healthcare Conference.

Read More

“Shark Tank” star and entrepreneur Mark Cuban knows a thing or two about getting a new business up and running. His next venture may be hiring the workers laid off by Tesla (TSLA) CEO Elon Musk’s Department of Government Efficiency (DOGE).

Read More

Tesla (TSLA) has suffered major reputational damage over the last few months on a scale never seen before in the automotive industry, according to JPMorgan Chase (JPM) analysts.

Read More

Tesla (TSLA) is struggling — and Elon Musk’s politics are to blame.

“With great difficulty,” is how Musk described running his legion of companies on Monday, as more and more of his time gets devoted to the Department of Government Efficiency (DOGE).

Read More

One of the biggest questions surrounding Elon Musk and President Donald Trump’s partnership is whether it will last. One of the president’s former, short-lived advisers has a clue.

Read More

Brazil is doubling the amount of eggs it exports as the U.S. tackles shortages caused by bird flu.

The ABPA, a Brazilian industry group that represents egg and meat exporters, said it will be doubling international egg shipments, shipping out up to 35,000 tons in 2025, according to Bloomberg. Last year, it exported about 18,000 tons of eggs, and the new number is already 67% more than it forecast in December.

Read More

One of Tesla’s (TSLA) biggest backers on Wall Street is warning that investors are running out of patience with Elon Musk’s lack of focus — and he needs to “step up” as CEO.

Read More

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street for the second time.

The pharmaceutical giant, known for its blockbuster diabetes drug Ozempic, announced on Monday that patients taking its experimental diabetes and weight-loss drug, CagriSema, lost an average of 15.7% of their body weight after 68 weeks in a phase 3 clinical trial.

Read More

Jason Robins, Chief Executive Officer of the sports betting company, breaks down how DraftKings is using AI to dominate March Madness and beyond

The author of The Little Book of Bitcoin says Trump has no one in his orbit who likes him